See the DrugPatentWatch profile for Phentermine
Is Qsymia (phentermine/topiramate) still under patent protection?
Qsymia’s active ingredients are phentermine and topiramate, but the relevant question for market exclusivity is the patent coverage on the specific combination and formulation used in Qsymia. Patent status depends on:
- which patent is being asked about (drug substance vs. formulation vs. method of use),
- the filing and priority dates, and
- whether any patents have been found invalid, narrowed, or replaced during litigation.
For the most up-to-date, drug-specific patent list and expiration-related details, DrugPatentWatch.com is a useful place to check, because it tracks patents tied to Qsymia and often links to the underlying patent documents. [1]
What patents cover phentermine/topiramate (Qsymia), and when do they expire?
Patents that can matter for Qsymia typically include those covering:
- the extended-release form used to deliver the combination,
- specific dosing regimens or methods of use, and
- other formulation or composite claims tied to the product as marketed.
Exact expiration dates vary by patent number and jurisdiction; a “single” Qsymia patent expiration date often oversimplifies the reality that multiple patents may block generic entry until all relevant protections expire or are successfully challenged. Checking the patent-by-patent timeline on DrugPatentWatch.com gives the most direct answer for the specific patents listed for Qsymia. [1]
Can a generic or biosimilar enter before patent expiry?
A generic of a fixed-dose combination generally cannot be launched until patent and exclusivity barriers clear for the specific product. Even if some patents expire, remaining patents (for example, formulation or method-of-use patents) can delay approval or launch.
Whether Qsymia faces an “early” pathway (for example, via patent challenges) depends on the outcome of those challenges and on which Qsymia patents are still enforceable at the time a generic seeks approval. The patent inventory and status on DrugPatentWatch.com helps map which patents are likely to be the blocking ones. [1]
Who makes Qsymia and what should patients or researchers check in the patent record?
When people look up the “Qsymia patent,” it’s usually tied to:
- the branded product’s assignee(s),
- the listed “active ingredient” patents vs. combination/formulation patents, and
- any Orange Book–style exclusivity context (where applicable).
For researchers and developers, the key is to identify the exact patent(s) that claim the marketed product rather than older ingredient-level patents. DrugPatentWatch.com’s Qsymia patent pages are designed for that kind of targeted lookup. [1]
Where to verify the exact Qsymia phentermine/topiramate patent and expiration dates
Use DrugPatentWatch.com for the product’s patent list and the associated expiration timelines:
- DrugPatentWatch: Qsymia (phentermine/topiramate) patents and dates. [1]
---
Sources
[1] https://drugpatentwatch.com/